{"id":"purified-inactivated-rabies-vaccine","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Injection site reactions (pain, erythema, swelling)"},{"rate":"5-15","effect":"Headache"},{"rate":"5-10","effect":"Myalgia"},{"rate":"1-5","effect":"Fever"},{"rate":"1-5","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL2107962","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains inactivated (killed) rabies virus particles that trigger both humoral (antibody) and cell-mediated immune responses without causing disease. Upon exposure to rabies virus, the pre-existing immunity provides rapid neutralization of the virus before it can reach the central nervous system. This is typically administered post-exposure in combination with rabies immunoglobulin for non-vaccinated individuals, or as pre-exposure prophylaxis for high-risk populations.","oneSentence":"Purified inactivated rabies vaccine stimulates the immune system to produce antibodies and cellular immunity against rabies virus, preventing infection after exposure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:30:41.101Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rabies post-exposure prophylaxis"},{"name":"Rabies pre-exposure prophylaxis in high-risk individuals"}]},"trialDetails":[{"nctId":"NCT07183371","phase":"PHASE2","title":"A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2025-12-15","conditions":"Malaria,Falciparum","enrollment":360},{"nctId":"NCT04127786","phase":"PHASE3","title":"Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen to Children and Adults and as Single Booster Dose to a Subset of Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-10-21","conditions":"Rabies, Healthy Volunteers","enrollment":1708},{"nctId":"NCT07147400","phase":"PHASE2","title":"Pfs230D1 + R21 in Matrix-M1 in African School Children and Adults","status":"RECRUITING","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2025-08-22","conditions":"Prevention of Malaria Transmission and Clinical Malaria","enrollment":1200},{"nctId":"NCT04478084","phase":"PHASE3","title":"Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adult and Pediatric Population in Thaïland","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-08-04","conditions":"Rabies (Healthy Volunteers)","enrollment":403},{"nctId":"NCT04594551","phase":"PHASE3","title":"Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adults in Thaïland","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-10-11","conditions":"Rabies (Healthy Volunteers)","enrollment":201},{"nctId":"NCT03965962","phase":"PHASE3","title":"Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-07-01","conditions":"Rabies (Healthy Volunteers)","enrollment":640},{"nctId":"NCT04019444","phase":"PHASE1","title":"Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-09-19","conditions":"Rabies, Rabies Immunisation","enrollment":50},{"nctId":"NCT05135273","phase":"PHASE1","title":"Study of the Transmission-Blocking Vaccine Pfs230D1-EPA/Matrix-M Against Malaria in Adults in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-10-22","conditions":"Malaria,Falciparum","enrollment":80},{"nctId":"NCT05937113","phase":"PHASE4","title":"Safety and Immunogenicity of the Inactivated Rabies Vaccine RABIVAX-S Administered Intramuscularly and Intradermally","status":"COMPLETED","sponsor":"Vietnam Military Medical University","startDate":"2020-06-13","conditions":"Rabies","enrollment":220},{"nctId":"NCT04232943","phase":"PHASE1","title":"Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge Study in Healthy Adults","status":"COMPLETED","sponsor":"PATH","startDate":"2020-01-22","conditions":"Polio","enrollment":87},{"nctId":"NCT03145766","phase":"PHASE2","title":"Immunogenicity and Safety of a Purified Vero Rabies Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2017-04-17","conditions":"Rabies Virus","enrollment":320},{"nctId":"NCT03656198","phase":"PHASE4","title":"Non-specific Effects of Rabies Vaccine","status":"COMPLETED","sponsor":"Ross University School of Veterinary Medicine","startDate":"2018-08-29","conditions":"Influenza-like Illness, Upper Respiratory Disease, Diarrhea","enrollment":546},{"nctId":"NCT03741270","phase":"PHASE4","title":"Safety of Rabivax-S for Pre-exposure Prophylaxis","status":"COMPLETED","sponsor":"Ross University School of Veterinary Medicine","startDate":"2018-10-24","conditions":"Rabies Vaccine Adverse Reaction","enrollment":159},{"nctId":"NCT01784874","phase":"PHASE2","title":"Comparison of Purified Vero Rabies Vaccine, Serum Free With Human Diploid Cell Vaccine in Pre-exposure Use","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2013-02","conditions":"Rabies","enrollment":408},{"nctId":"NCT01877395","phase":"PHASE2","title":"Study of Purified Vero Rabies Vaccine and Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post-exposure Regimen","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2013-06","conditions":"Rabies","enrollment":342},{"nctId":"NCT00948272","phase":"PHASE2","title":"Study of Purified Vero Rabies Vaccine Serum Free Compared With Reference Purified Vero Rabies Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-07","conditions":"Rabies","enrollment":384},{"nctId":"NCT01339312","phase":"PHASE3","title":"Study of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-04","conditions":"Rabies, Rabies Virus","enrollment":816},{"nctId":"NCT01365494","phase":"PHASE4","title":"Immunogenicity and Safety of Rabies Vaccine, Administered With Two Different Simulated Post Exposure Schedules","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-07","conditions":"Rabies","enrollment":250},{"nctId":"NCT01810731","phase":"PHASE2, PHASE3","title":"Safety and Immunogenicity Study of Influenza Vaccines in HIV-infected and HIV-uninfected Pregnant Women in Western Kenya","status":"WITHDRAWN","sponsor":"Centers for Disease Control and Prevention","startDate":"2014-04","conditions":"Influenza, Human, HIV, Malaria","enrollment":""},{"nctId":"NCT01044199","phase":"NA","title":"Study of Intradermal Administration of PCEC Rabies Vaccine","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2009-02","conditions":"Rabies Prevention, Rabies Exposure","enrollment":130},{"nctId":"NCT00694460","phase":"PHASE2","title":"Evalution of Immunogenicity, Safety and Booster Response of a Rabies Vaccine Administered Concomitantly With Japanese Encephalitis Vaccine in Toddlers","status":"COMPLETED","sponsor":"Novartis","startDate":"2002-08","conditions":"Rabies, Japanese Encephalitis, Pre-Exposure Prophylaxis","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Verorab®","Verorab"],"phase":"phase_3","status":"active","brandName":"Purified inactivated rabies vaccine","genericName":"Purified inactivated rabies vaccine","companyName":"Sanofi Pasteur, a Sanofi Company","companyId":"sanofi","modality":"Biologic","firstApprovalDate":"","aiSummary":"Purified inactivated rabies vaccine stimulates the immune system to produce antibodies and cellular immunity against rabies virus, preventing infection after exposure. Used for Rabies post-exposure prophylaxis, Rabies pre-exposure prophylaxis in high-risk individuals.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}